Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly.

PubWeight™: 2.38‹?› | Rank: Top 2%

🔗 View Article (PMC 240514)

Published in J Virol on January 01, 1991

Authors

R P Bennett1, S Rhee, R C Craven, E Hunter, J W Wills

Author Affiliations

1: Department of Biochemistry and Molecular Biology, Louisiana State University Medical Center-Shreveport 71130.

Articles citing this

Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67

An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J Virol (1994) 5.87

Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92

Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src. J Virol (1991) 4.25

Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol (1996) 3.97

A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding. J Virol (1999) 3.92

Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71

Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein. J Virol (1995) 2.76

Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J Virol (1991) 2.65

Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein. J Virol (1993) 2.40

Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23

The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles. J Virol (1992) 2.17

The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1. Proc Natl Acad Sci U S A (1993) 1.97

Genetic determinants of Rous sarcoma virus particle size. J Virol (1998) 1.67

Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization. J Virol (2006) 1.52

Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers. J Virol (1991) 1.48

Differential proteolytic processing leads to multiple forms of the CA protein in avian sarcoma and leukemia viruses. J Virol (1995) 1.45

trans-acting viral protease is necessary and sufficient for activation of avian leukosis virus reverse transcriptase. J Virol (1991) 1.45

A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity. J Virol (1996) 1.43

A large extension to HIV-1 Gag, like Pol, has negative impacts on virion assembly. PLoS One (2012) 1.41

Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera. J Virol (2000) 1.36

Processing of avian retroviral gag polyprotein precursors is blocked by a mutation at the NC-PR cleavage site. J Virol (1992) 1.18

Type D retrovirus Gag polyprotein interacts with the cytosolic chaperonin TRiC. J Virol (2001) 1.14

Irregular and Semi-Regular Polyhedral Models for Rous Sarcoma Virus Cores. Comput Math Methods Med (2008) 1.12

Transposition of a Ty3 GAG3-POL3 fusion mutant is limited by availability of capsid protein. J Virol (1992) 1.07

Analysis of Rous sarcoma virus Gag protein by mass spectrometry indicates trimming by host exopeptidase. J Virol (1996) 1.05

Overlapping roles of the Rous sarcoma virus Gag p10 domain in nuclear export and virion core morphology. J Virol (2007) 1.00

Orthoretroviral-like prototype foamy virus Gag-Pol expression is compatible with viral replication. Retrovirology (2011) 0.96

The Structure of Immature Virus-Like Rous Sarcoma Virus Gag Particles Reveals a Structural Role for the p10 Domain in Assembly. J Virol (2015) 0.95

Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: rethinking the "fireman's grip" hypothesis. Protein Sci (2000) 0.92

Complementation studies with Rous sarcoma virus gag and gag-pol polyprotein mutants. J Virol (1992) 0.87

Transport and processing of the Rous sarcoma virus Gag protein in the endoplasmic reticulum. J Virol (1996) 0.86

The major site of phosphorylation within the Rous sarcoma virus MA protein is not required for replication. J Virol (1998) 0.84

Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication. J Virol (1996) 0.80

Functional complementation of nucleocapsid and late domain PTAP mutants of human immunodeficiency virus type 1 during replication. Virology (2008) 0.80

Phosphorylation and proteolytic cleavage of gag proteins in budded simian immunodeficiency virus. J Virol (2005) 0.79

Potential role for CA-SP in nucleating retroviral capsid maturation. J Virol (2014) 0.78

Insertion of capsid proteins from nonenveloped viruses into the retroviral budding pathway. J Virol (2001) 0.77

Functional Equivalence of Retroviral MA Domains in Facilitating Psi RNA Binding Specificity by Gag. Viruses (2016) 0.75

Articles cited by this

Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol (1987) 66.52

Nucleotide sequence of Rous sarcoma virus. Cell (1983) 17.80

Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science (1989) 7.15

Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region. Cell (1988) 7.14

Complete mutagenesis of the HIV-1 protease. Nature (1989) 5.16

Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature (1989) 4.80

A structural model for the retroviral proteases. Nature (1987) 4.78

Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells. J Virol (1989) 4.60

Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles. J Virol (1990) 4.22

Properties of avian retrovirus particles defective in viral protease. J Virol (1990) 4.03

Two efficient ribosomal frameshifting events are required for synthesis of mouse mammary tumor virus gag-related polyproteins. Proc Natl Acad Sci U S A (1987) 3.84

Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43

Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11

Localization of RNA tumor virus polypeptides. I. Isolation of further virus substructures. Virology (1973) 2.94

Expression of the gag-pol fusion protein of Moloney murine leukemia virus without gag protein does not induce virion formation or proteolytic processing. J Virol (1988) 2.74

Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature (1989) 2.72

X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes. Nature (1989) 2.66

In vitro cleavage of avian retrovirus gag proteins by viral protease p15. Virology (1979) 2.64

Retroviral proteinases. Curr Top Microbiol Immunol (1990) 2.41

Retroviral proteases: first glimpses at the anatomy of a processing machine. Cell (1989) 2.24

Nucleotide sequence of the Syrian hamster intracisternal A-particle gene: close evolutionary relationship of type A particle gene to types B and D oncovirus genes. J Virol (1985) 2.20

Molecular modeling of the HIV-1 protease and its substrate binding site. Science (1989) 1.60

Amino acid sequence of p15 from avian myeloblastosis virus complex. Biochemistry (1981) 1.58

Partial purification and substrate analysis of bacterially expressed HIV protease by means of monoclonal antibody. EMBO J (1988) 1.46

Synthetic peptides as substrates and inhibitors of a retroviral protease. Proc Natl Acad Sci U S A (1988) 1.41

Activity of avian retroviral protease expressed in Escherichia coli. J Virol (1988) 1.34

Retrovirus protease characterized as a dimeric aspartic proteinase. J Virol (1989) 1.30

Avian retroviral protease and cellular aspartic proteases are distinguished by activities on peptide substrates. J Biol Chem (1989) 1.29

Articles by these authors

Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71

Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67

Nucleotide sequence of Mason-Pfizer monkey virus: an immunosuppressive D-type retrovirus. Cell (1986) 6.07

Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids. J Virol (1987) 5.68

Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92

DNA content, kinetic complexity, and the ploidy question in Candida albicans. Mol Cell Biol (1982) 4.64

Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells. J Virol (1989) 4.60

A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci U S A (1994) 4.43

Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src. J Virol (1991) 4.25

Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol (1992) 4.20

Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein. J Virol (1997) 4.08

Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol (1996) 3.97

Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci U S A (2000) 3.83

Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71

A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus. Cell (1990) 3.70

A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J Virol (1998) 3.69

Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol (1992) 3.54

A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol (1999) 3.49

Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43

Mutants of the Rous sarcoma virus envelope glycoprotein that lack the transmembrane anchor and cytoplasmic domains: analysis of intracellular transport and assembly into virions. J Virol (1987) 3.28

Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release. J Virol (1993) 3.19

Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells. Proc Natl Acad Sci U S A (1991) 3.18

Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11

WW domains and retrovirus budding. Nature (1996) 3.10

Oligomeric structure of a prototype retrovirus glycoprotein. Proc Natl Acad Sci U S A (1988) 3.06

Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras. J Virol (1999) 2.90

Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A (1994) 2.88

Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein. J Virol (1995) 2.76

Mutational analysis of the major homology region of Mason-Pfizer monkey virus by use of saturation mutagenesis. J Virol (1992) 2.56

Complete sequence of the Rous sarcoma virus env gene: identification of structural and functional regions of its product. J Virol (1983) 2.53

Widespread West Nile virus activity, eastern United States, 2000. Emerg Infect Dis (2001) 2.52

Repetitive DNA of Candida albicans: nuclear and mitochondrial components. J Bacteriol (1984) 2.52

Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane. J Virol (1990) 2.51

Amino acid substitutions within the matrix protein of type D retroviruses affect assembly, transport and membrane association of a capsid. EMBO J (1991) 2.51

Loss of virulence associated with absence of flagellum in an isogenic mutant of Pseudomonas aeruginosa in the burned-mouse model. Infect Immun (1982) 2.48

Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein. J Virol (1993) 2.40

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol (2001) 2.38

Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly. J Virol (1990) 2.34

Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23

Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J (1997) 2.23

Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescue. J Virol (1998) 2.18

Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein that block processing to gp85 and gp37. J Virol (1987) 2.07

The molecular basis of substrate channeling. J Biol Chem (1999) 2.06

Structural requirements for marbox function in transcriptional activation of mar/sox/rob regulon promoters in Escherichia coli: sequence, orientation and spatial relationship to the core promoter. Mol Microbiol (1999) 2.00

Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol (1993) 1.99

Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity. J Virol (1994) 1.97

A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol (1995) 1.93

Intracellular trafficking of the UL11 tegument protein of herpes simplex virus type 1. J Virol (2001) 1.90

Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol (1999) 1.89

Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro. J Virol (1996) 1.85

Circular mitochondrial genome of Candida albicans contains a large inverted duplication. J Bacteriol (1985) 1.84

Polypeptides of Mason-Pfizer monkey virus. I. Synthesis and processing of the gag-gene products. Virology (1984) 1.83

A viral protease-mediated cleavage of the transmembrane glycoprotein of Mason-Pfizer monkey virus can be suppressed by mutations within the matrix protein. Proc Natl Acad Sci U S A (1992) 1.83

Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria. J Virol (1995) 1.81

A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J Virol (1992) 1.80

Distinct subsets of retroviruses encode dUTPase. J Virol (1992) 1.80

Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein. J Virol (1996) 1.70

Efficiency and selectivity of RNA packaging by Rous sarcoma virus Gag deletion mutants. J Virol (1994) 1.70

Avian reticuloendotheliosis viruses: evolutionary linkage with mammalian type C retroviruses. J Virol (1979) 1.68

The mechanism for genetic recombination in the avian retroviruses. Curr Top Microbiol Immunol (1978) 1.67

Genetic determinants of Rous sarcoma virus particle size. J Virol (1998) 1.67

Flagellar preparations from Pseudomonas aeruginosa: isolation and characterization. Infect Immun (1982) 1.67

Biological techniques for avian sarcoma viruses. Methods Enzymol (1979) 1.67

Motility and chemotaxis of three strains of Pseudomonas aeruginosa used for virulence studies. Can J Microbiol (1981) 1.58

Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions. J Virol (2001) 1.55

Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation. J Virol (1995) 1.54

A charged amino acid substitution within the transmembrane anchor of the Rous sarcoma virus envelope glycoprotein affects surface expression but not intracellular transport. J Cell Biol (1987) 1.50

Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein define a requirement for dibasic residues for intracellular cleavage. J Virol (1992) 1.50

Particle size determinants in the human immunodeficiency virus type 1 Gag protein. J Virol (1998) 1.48

Zymogen proteolysis within the pancreatic acinar cell is associated with cellular injury. Am J Physiol (1998) 1.47

Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins. J Virol (1993) 1.47

Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol (1992) 1.46

Amino-terminal amino acid sequence of the major structural polypeptides of avian retroviruses: sequence homology between reticuloendotheliosis virus p30 and p30s of mammalian retroviruses. Proc Natl Acad Sci U S A (1978) 1.46

Recent advances and remaining problems in HIV assembly. AIDS (1998) 1.46

Differential proteolytic processing leads to multiple forms of the CA protein in avian sarcoma and leukemia viruses. J Virol (1995) 1.45

AIDS biosafety. Science (1991) 1.44

A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity. J Virol (1996) 1.43

Pausing of reverse transcriptase on retroviral RNA templates is influenced by secondary structures both 5' and 3' of the catalytic site. Nucleic Acids Res (1998) 1.43

Inhibition of Rous sarcoma virus replication by 2-deoxyglucose and tunicamycin: identification of an unglycosylated env gene product. J Virol (1979) 1.42

The membrane-binding domain of the Rous sarcoma virus Gag protein. J Virol (1996) 1.39

Viral DNA synthesis defects in assembly-competent Rous sarcoma virus CA mutants. J Virol (2001) 1.39

The three-dimensional solution structure of the matrix protein from the type D retrovirus, the Mason-Pfizer monkey virus, and implications for the morphology of retroviral assembly. EMBO J (1997) 1.38

Functional analysis of the core human immunodeficiency virus type 1 packaging signal in a permissive cell line. J Virol (1998) 1.38

Oligomerization of the hydrophobic heptad repeat of gp41. J Virol (1995) 1.38

Effect of cloned human interferons on protein synthesis and morphogenesis of herpes simplex virus. J Virol (1985) 1.38

Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera. J Virol (2000) 1.36

Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells. J Virol (1990) 1.36

Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. J Virol (1994) 1.35

V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology (1992) 1.35

Identification of a cytoplasmic targeting/retention signal in a retroviral Gag polyprotein. J Virol (1999) 1.33

An avian sarcoma virus mutant that is temperature sensitive for virion assembly. Virology (1976) 1.33

Repositioning basic residues in the M domain of the Rous sarcoma virus gag protein. J Virol (2000) 1.33

The crystal structure of the nitrogen regulation fragment of the yeast prion protein Ure2p. Proc Natl Acad Sci U S A (2001) 1.31

Alterations in the transport and processing of Rous sarcoma virus envelope glycoproteins mutated in the signal and anchor regions. J Cell Biochem (1983) 1.31